Multiple primary malignant tumors of the head and neck.

Multiple primary malignant tumors associated with an index cancer in the head and neck are gaining attention as more patients survive their initial primary disease, the longevity of the population at large increases, health care delivery becomes more readily available, and sophisticated diagnostic technology is developed. Forty-four patients with multiple primary cancer in whom the index neoplasm was inthe head and neck are reported. This group comprises 17 per cent of the patients with head and neck cancer treated at the Detroit General Hospital in the last 10 years. Forty-seven per cent of the cancers occurred simultaneously, 10 per cent were synchronous (discovered within six months), and 43 per cent were metachronous (discovered later than six months). Eighty-six per cent of the patients are dead; 75 per cent died within one year after the diagnosis of the secondary primary cancer. Patients with simultaneously occurring malignant tumors appeared to have a somewhat poorer prognosis than those with metachronously occurring tumors. Although the highest incidence of multiple primary malignant tumors occurs in the first year, a consistent high incidence puts the patient with a solitary neoplasm at risk well beyond the three to five years of survival usually considered as "cure." Although no factor other than coincidence has been proved to be involved in the pattern of occurrence of multiple primary neoplasms of different tissues or organs, this study does corroborate other reported data that emphasize that patients with head and neck cancer are at greater risk of developing a second primary malignant tumor in the multicentric vicinity of the original lesion, and in the esophagus and lung than the general population. A program of management and post-treatment surveillance is presented. The potential for new primary malignant neoplasms to develop in the multicentric vicinity of the original lesion and in remote organs cannot be approached with detached curiosity.